Journal of the American Academy of Child & Adolescent Psychiatry
New researchA Longitudinal Follow-up Study Examining Adolescent Depressive Symptoms as a Function of Prior Anxiety Treatment
Section snippets
Adolescence as a Period of Risk for Depression
The transition into adolescence may represent a sensitive period for the development and prevention of depressive symptoms. The transitional period between preadolescence and early adolescence, beginning with the onset of pubertal changes around age 9 or 10 years,11 involves dramatic multi-systemic changes that influence social and affective functioning and learning.12 These include rapid physical growth, changes in endocrine function and neural development, renegotiation of family and peer
Participants
Participants were 80 youth who met DSM-IV35 criteria for a diagnosis of generalized anxiety disorder (75%), separation anxiety disorder (20%), and/or social anxiety disorder (24%), who previously received CBT (n = 54) or CCT (n = 26) as part of a randomized clinical trial37 and were subsequently enrolled in a follow-up study (Figure 1). Participants were 9 to 14 years old (mean = 11.21, SD = 1.47) at the pretreatment assessment and 11 to 17 years of age (mean = 13.56, SD = 1.52) at the 2-year
Results
The covariates added in Step 1 (gender, baseline depressive symptoms, and receipt of additional psychological services during the 2-year follow-up enrollment) collectively predicted 2-year depressive symptom scores (F4,75 = 5.01, p = .001, R2 = 0.211, adjusted R2 = 0.169). Specifically, gender (girls>boys: β = 0.463, 95% CI = 0.038−0.888], p = .033) and self-reported enrollment in community treatment during the follow-up interval (enrolled>unenrolled: β = 0.781, 95% CI = 0.312−1.250, p = .001)
Discussion
The present results indicate that anxious youth who were successfully treated with CBT for an anxiety disorder during preadolescence or early adolescence showed lower levels of depressive symptoms later in adolescence compared to anxious youth who were not successfully treated. This association between early anxiety treatment and decreased development of depressive symptoms was specific to CBT and was not found for those who responded acutely to a supportive CCT. This is the first study to
References (55)
- et al.
Are adolescents changed by an episode of major depression?
J Am Academy Child Adolesc Psychiatry
(1994) - et al.
Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS)
J Am Acad Child Adolesc Psychiatry
(2006) - et al.
The emergence of depression in adolescence: development of the prefrontal cortex and the representation of reward
Neurosci Biobehav Rev
(2008) - et al.
Mood disorders in children and adolescents: an epidemiologic perspective
Biol Psychiatry
(2001) - et al.
Effects of psychotherapy for anxiety in children and adolescents: a meta-analytic review
Clin Psychol Rev
(2012) - et al.
A multisite, randomized controlled trial for children with sexual abuse-related PTSD symptoms
J Am Acad Child Adolesc Psychiatry
(2004) - et al.
Treating sexually abused children: 1 year follow-up of a randomized controlled trial
Child Abuse Neglect
(2005) - et al.
Defining treatment response and remission in child anxiety: signal detection analysis using the Pediatric Anxiety Rating Scale
J Am Acad Child Adolesc Psychiatry
(2013) - et al.
Prefrontal-subcortical pathways mediating successful emotion regulation
Neuron
(2008) Gender differences in emotional responses to interpersonal stress during adolescence
J Adolesc Health
(2002)
Epidemiology of women and depression
J Affect Disord
Brief cognitive-behavioral therapy for anxious youth: feasibility and initial outcomes
Cogn Behav Pract
The Global Burden of Disease
Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010
PLoS Med
Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Study
Arch Gen Psychiatry
National trends in the prevalence and treatment of depression in adolescents and young adults
Pediatrics
Depressed adolescents grown up
JAMA
Adult mental health and social outcomes of adolescent girls with depression and conduct disorder
Dev Psychopathol
The prevention of depressive symptoms in children and adolescents: a meta-analytic review [see Comment]
J Consult Clin Psychol
Prevention targets for child and adolescent depression
JAMA Psychiatry
Recent data on pubertal milestones in United States children: the secular trend toward earlier development
Int J Androl
Importance of investing in adolescence from a developmental science perspective
Nature
Adolescent development
Annu Rev Psychol
Adolescent brain development: a period of vulnerabilities and opportunities
Ann N Y Acad Sci
Neurobehavioral changes in adolescence
Curr Direct Psychol Sci
Why do anxious children become depressed teenagers? The role of social evaluative threat and reward processing
Psychol Med
Antecedents of new-onset major depressive disorder in children and adolescents at high familial risk
JAMA Psychiatry
Cited by (0)
This work was supported by National Institute of Mental Health grant MH091327. Support for research participant recruitment was also provided by the Clinical and Translational Science Institute, University of Pittsburgh (NIH/NCRR/CTSA grant UL1 RR024153).
The authors are grateful to the participants and their families. They are also grateful to Anthony Mannarino, PhD, of Allegheny General Hospital, for clinical supervision, and to the following University of Pittsburgh research staff and trainees for their assistance in data collection, analysis, and provision of clinical services: Laura Trubnick, Jennifer Jacubcak, Marcus Min, Jessica Wilson, Marcie Walker, Kara Colaizzi, Melissa Milbert, Katie Burkhouse, Rebecca Hartjen, Christine Larson, Abigail Martin, Kristin Pracht, Karen Garelik, Sherri Karas, Grace Chung, Suzanne Meller, Rosalind Elliott, Patricia Tan, Kristy Benoit Allen, Caroline Oppenheimer, Kyung Hwa Lee, and Lindsey Stone.
Disclosure: Drs. Silk, Price, Ryan, Forbes, Siegle, Dahl, McMakin, Kendall, Ladouceur and Ms. Rosen report no biomedical financial interests or potential conflicts of interest.